Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)